Prevention of Malignancy Following Hydatidiform Mole With Vitamin A

Andri Andrijono, Muhammad Muhilal, Emil Taufik, Meny Hartati, Ria Kodariah, Wan Leli Heffen

Research output: Contribution to journalArticlepeer-review


The aim of this study was to demonstrate the role of vitamin A as chemoprevention for malignancy following hydatidiform mole. This study was a series of trials. Two supporting studies, i.e. the study on the expression of RPB (retinol binding protein) receptor, the study on apoptosis activity in trophoblastic cells with the administration of retinoic has been conducted. The main study is clinical trial on the prevention of malignancy following hydatidiform mole with vitamin A. The study was a randomized double-blind clinical trial. Subjects of the study were patients with complete hydatidiform mole. Placebo and vitamin A were administered at 200,000 IU per day until patients were declared cured or MTD. Variables of outcome were the incidence of regression and MTD which were established based on WHO criteria. From as many as 21 specimens of with immunohistochemistry study, we found RBP receptor expression in trophoblastic cells. In the study on apoptosis activity in the culture of trophoblastic cells receiving retinoic, we found apoptosis activity. Apoptosis activity in the control was 60%, in ATRA of 50 μg/ml was 89.54%, of 100 μg/ml was 87.23%, of 150 μg/ml was 94.63%, and of 200 μg/ml was 94,83%. The clinical trial found 67 cases admitted to the study. As many as 2 cases were lost from observation, and 3 cases experienced pregnancy during observation. The incidence rate of MTD in the control group was 28.57%, and in the therapy group 6.25%.
Original languageEnglish
JournalJournal of the Indonesian Medical Association : Majalah Kedokteran Indonesia
Publication statusPublished - 2009


Dive into the research topics of 'Prevention of Malignancy Following Hydatidiform Mole With Vitamin A'. Together they form a unique fingerprint.

Cite this